PRIMARY MISSION:

To prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research.

SECONDARY MISSION:

To refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.

APPROACH:

Members will work together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.

A Catalyst for Antiphospholipid
Syndrome Research

March 2011 - The treatment of the serious, potentially fatal autoimmune clotting disorder antiphospholipid syndrome (APS) has, in general, been empiric and based on various approaches to inhibit the clotting system.
Read More

Little-Studied Blood Syndrome Gains
Researchers' Attention

March 15, 2011 - Motivated by the lack of treatment options for patients with antiphospholipid syndrome (APS), rheumatology researchers convened an international committee to address the problem directly.
Read More

International Summit Held
to Stimulate Collaborative Clinical Research on Antiphospholipid Syndrome

November 2, 2010 - Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages.
Read More

PRIMARY MISSION:

SECONDARY MISSION:

APPROACH:

A Catalyst for Antiphospholipid Syndrome Research

Little-Studied Blood Syndrome Gains Researchers' Attention

International Summit Held to Stimulate Collaborative Clinical Research on Antiphospholipid Syndrome

A Catalyst for Antiphospholipid
Syndrome Research

Little-Studied Blood Syndrome Gains
Researchers' Attention

International Summit Held
to Stimulate Collaborative Clinical Research on Antiphospholipid Syndrome